Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Rabinovich NR, McInnes P, Klein DL, Hall BF. Vaccine technologies: view to the future.Science. 1994;265:1401–4. [DOI] [PubMed]
Moore ZS, Seward JF, Lane JM. Smallpox.Lancet. 2006;367:425–35. [DOI] [PubMed]
Malagón T, Drolet M, Boily M, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.Lancet Infect Dis. 2012;12:781–9. [DOI] [PubMed]
Kirby T. FDA approves new upgraded Gardasil 9.Lancet Oncol. 2015;16:e56. [DOI] [PubMed]
Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy.Mol Cancer. 2021;20:33. [DOI] [PubMed] [PMC]
Pollard C, Koker SD, Saelens X, Vanham G, Grooten J. Challenges and advances towards the rational design of mRNA vaccines.Trends Mol Med. 2013;19:705–13. [DOI] [PubMed]
Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo.Science. 1990;247:1465–8. [DOI] [PubMed]
Jirikowski GF, Sanna PP, Maciejewski-Lenoir D, Bloom FE. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA.Science. 1992;255:996–8. [DOI] [PubMed]
Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology.Curr Opin Immunol. 2020;65:14–20. [DOI] [PubMed]
Naik R, Peden K. Regulatory Considerations on the Development of mRNA Vaccines. In: Yu D, Petsch B, editors. mRNA Vaccines. Cham: Springer; 2022. pp. 187–205. [DOI] [PubMed]
Rice AM, Morales AC, Ho AT, Mordstein C, Mühlhausen S, Watson S, et al. Evidence for Strong Mutation Bias toward, and Selection against, U Content in SARS-CoV-2: Implications for Vaccine Design.Mol Biol Evol. 2021;38:67–83.Erratum in: Mol Biol Evol. 2021;38:5210. [DOI] [PubMed] [PMC]
Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.Lancet. 2017;390:1511–20. [DOI] [PubMed]
Kirschman JL, Bhosle S, Vanover D, Blanchard EL, Loomis KH, Zurla C, et al. Characterizing exogenous mRNA delivery, trafficking, cytoplasmic release and RNA-protein correlations at the level of single cells.Nucleic Acids Res. 2017;45:e113. [DOI] [PubMed] [PMC]
Wroblewska L, Kitada T, Endo K, Siciliano V, Stillo B, Saito H, et al. Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery.Nat Biotechnol. 2015;33:839–41. [DOI] [PubMed] [PMC]
He S, Fan W, Wu N, Zhu J, Miao Y, Miao X, et al. Lipid-Based Liquid Crystalline Nanoparticles Facilitate Cytosolic Delivery of siRNA via Structural Transformation.Nano Lett. 2018;18:2411–19. [DOI] [PubMed]
Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality.Genome Med. 2017;9:60. [DOI] [PubMed] [PMC]
Zhu G, Zhang F, Ni Q, Niu G, Chen X. Efficient Nanovaccine Delivery in Cancer Immunotherapy.ACS Nano. 2017;11:2387–92. [DOI] [PubMed]
Blakney AK, Zhu Y, McKay PF, Bouton CR, Yeow J, Tang J, et al. Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer.ACS Nano. 2020;14:5711–27. [DOI] [PubMed] [PMC]
Egan KP, Hook LM, Naughton A, Pardi N, Awasthi S, Cohen GH, et al. An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection.PLoS Pathog. 2020;16:e1008795. [DOI] [PubMed] [PMC]
Wang F, Xiao W, Elbahnasawy MA, Bao X, Zheng Q, Gong L, et al. Optimization of the Linker Length of Mannose-Cholesterol Conjugates for Enhanced mRNA Delivery to Dendritic Cells by Liposomes.Front Pharmacol. 2018;9:980. [DOI] [PubMed] [PMC]
Kl W. mRNA vaccines in the rheumatologist’s future.Semin Arthritis Rheum. 2024;64S:152325. [DOI] [PubMed]
Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective.NPJ Vaccines. 2020;5:11. [DOI] [PubMed] [PMC]
Pushko P, Lukashevich IS, Johnson DM, Tretyakova I. Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses.Viruses. 2024;16:428. [DOI] [PubMed] [PMC]
Lee MF, Long CM, Poh CL. Current status of the development of dengue vaccines.Vaccine X. 2024;22:100604. [DOI] [PubMed] [PMC]
Folorunso OS, Sebolai OM. Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.Vaccines (Basel). 2020;8:341. [DOI] [PubMed] [PMC]
Kumar P, Bird C, Holland D, Joshi SB, Volkin DB. Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.Hum Vaccin Immunother. 2022;18:2154100. [DOI] [PubMed] [PMC]
Jefferson T, Rivetti A, Pietrantonj CD, Demicheli V. Vaccines for preventing influenza in healthy children.Cochrane Database Syst Rev. 2018;2:CD004879. [DOI] [PubMed] [PMC]
Wang N, Shang J, Jiang S, Du L. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses.Front Microbiol. 2020;11:298. [DOI] [PubMed] [PMC]
Hendy DA, Haven A, Bachelder EM, Ainslie KM. Preclinical developments in the delivery of protein antigens for vaccination.Expert Opin Drug Deliv. 2023;20:367–84. [DOI] [PubMed] [PMC]
Yadav T, Kumar S, Mishra G, Saxena SK. Tracking the COVID-19 vaccines: The global landscape.Hum Vaccin Immunother. 2023;19:2191577. [DOI] [PubMed] [PMC]
Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.Signal Transduct Target Ther. 2023;8:149. [DOI] [PubMed] [PMC]
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology.Nat Rev Drug Discov. 2018;17:261–79. [DOI] [PubMed] [PMC]
Krieg PA, Melton DA. Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs.Nucleic Acids Res. 1984;12:7057–70. [DOI] [PubMed] [PMC]
Pascolo S. Vaccination with messenger RNA.Methods Mol Med. 2006;127:23–40. [DOI] [PubMed]
Banerjee AK. 5'-terminal cap structure in eucaryotic messenger ribonucleic acids.Microbiol Rev. 1980;44:175–205. [DOI] [PubMed] [PMC]
Wickens M. How the messenger got its tail: addition of poly(A) in the nucleus.Trends Biochem Sci. 1990;15:277–81. [DOI] [PubMed]
Konarska MM, Padgett RA, Sharp PA. Recognition of cap structure in splicing in vitro of mRNA precursors.Cell. 1984;38:731–6. [DOI] [PubMed]
Munroe D, Jacobson A. mRNA poly(A) tail, a 3' enhancer of translational initiation.Mol Cell Biol. 1990;10:3441–55. [DOI] [PubMed] [PMC]
Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, et al. Characterization of a messenger RNA polynucleotide vaccine vector.Cancer Res. 1995;55:1397–400. [PubMed]
Kore AR, Shanmugasundaram M, Charles I, Vlassov AV, Barta TJ. Locked nucleic acid (LNA)-modified dinucleotide mRNA cap analogue: synthesis, enzymatic incorporation, and utilization.J Am Chem Soc. 2009;131:6364–5. [DOI] [PubMed]
Jani B, Fuchs R. In vitro transcription and capping of Gaussia luciferase mRNA followed by HeLa cell transfection.J Vis Exp. 2012;61:3702. [DOI] [PubMed] [PMC]
Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG.RNA. 2001;7:1486–95. [PubMed] [PMC]
Urbina F, Morales-Pison S, Maldonado E. Enzymatic Protein Biopolymers as a Tool to Synthetize Eukaryotic Messenger Ribonucleic Acid (mRNA) with Uses in Vaccination, Immunotherapy and Nanotechnology.Polymers (Basel). 2020;12:1633. [DOI] [PubMed] [PMC]
Whitelaw E, Coates A, Proudfoot NJ. Globin gene transcripts can utilize histone gene 3' end processing signals.Nucleic Acids Res. 1986;14:7059–70. [DOI] [PubMed] [PMC]
Doel MT, Carey NH. The translational capacity of deadenylated ovalbumin messenger RNA.Cell. 1976;8:51–8. [DOI] [PubMed]
Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.Blood. 2006;108:4009–17. [DOI] [PubMed]
Shabalina SA, Spiridonov NA, Kashina A. Sounds of silence: synonymous nucleotides as a key to biological regulation and complexity.Nucleic Acids Res. 2013;41:2073–94. [DOI] [PubMed] [PMC]
Kudla G, Lipinski L, Caffin F, Helwak A, Zylicz M. High guanine and cytosine content increases mRNA levels in mammalian cells.PLoS Biol. 2006;4:e180. [DOI] [PubMed] [PMC]
Homma K, Noguchi T, Fukuchi S. Codon usage is less optimized in eukaryotic gene segments encoding intrinsically disordered regions than in those encoding structural domains.Nucleic Acids Res. 2016;44:10051–61. [DOI] [PubMed] [PMC]
Zhong C, Wei P, Zhang YP. Enhancing functional expression of codon-optimized heterologous enzymes in Escherichia coli BL21(DE3) by selective introduction of synonymous rare codons.Biotechnol Bioeng. 2017;114:1054–64. [DOI] [PubMed]
Tusup M, French LE, Matos MD, Gatfield D, Kundig T, Pascolo S. Design of in vitro Transcribed mRNA Vectors for Research and Therapy.Chimia (Aarau). 2019;73:391–4. [DOI] [PubMed]
Kwon H, Kim M, Seo Y, Moon YS, Lee HJ, Lee K, et al. Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine.Biomaterials. 2018;156:172–93. [DOI] [PubMed]
Karikó K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.Nucleic Acids Res. 2011;39:e142. [DOI] [PubMed] [PMC]
Lukavsky PJ, Puglisi JD. Large-scale preparation and purification of polyacrylamide-free RNA oligonucleotides.RNA. 2004;10:889–93. [DOI] [PubMed] [PMC]
McKenna SA, Kim I, Puglisi EV, Lindhout DA, Aitken CE, Marshall RA, et al. Purification and characterization of transcribed RNAs using gel filtration chromatography.Nat Protoc. 2007;2:3270–7. [DOI] [PubMed]
Weissman D, Pardi N, Muramatsu H, Karikó K. HPLC purification of in vitro transcribed long RNA.Methods Mol Biol. 2013;969:43–54. [DOI] [PubMed]
Henninger HP, Hoffmann R, Grewe M, Schulze-Specking A, Decker K. Purification and quantitative analysis of nucleic acids by anion-exchange high-performance liquid chromatography.Biol Chem Hoppe Seyler. 1993;374:625–34. [DOI] [PubMed]
Green MR, Sambrook J. Isolation of Poly(A)+ Messenger RNA Using Magnetic Oligo(dT) Beads.Cold Spring Harb Protoc. 2019;2019. [DOI] [PubMed]
Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: Challenges and bottlenecks.Vaccine. 2021;39:2190–200. [DOI] [PubMed] [PMC]
Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, et al. A Comprehensive Review of mRNA Vaccines.Int J Mol Sci. 2023;24:2700. [DOI] [PubMed] [PMC]
Shepherd SJ, Issadore D, Mitchell MJ. Microfluidic formulation of nanoparticles for biomedical applications.Biomaterials. 2021;274:120826. [DOI] [PubMed] [PMC]
Desterro J, Bak-Gordon P, Carmo-Fonseca M. Targeting mRNA processing as an anticancer strategy.Nat Rev Drug Discov. 2020;19:112–29. [DOI] [PubMed]
Fabbri L, Chakraborty A, Robert C, Vagner S. The plasticity of mRNA translation during cancer progression and therapy resistance.Nat Rev Cancer. 2021;21:558–77. [DOI] [PubMed]
Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases.Signal Transduct Target Ther. 2022;7:166. [DOI] [PubMed] [PMC]
Pepini T, Pulichino A, Carsillo T, Carlson AL, Sari-Sarraf F, Ramsauer K, et al. Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design.J Immunol. 2017;198:4012–24. [DOI] [PubMed] [PMC]
Kormann MSD, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber-Jonat S, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.Nat Biotechnol. 2011;29:154–7. [DOI] [PubMed]
Jarallah SJ, Aldossary AM, Tawfik EA, Altamimi RM, Alsharif WK, Alzahrani NM, et al. GL67 lipid-based liposomal formulation for efficient siRNA delivery into human lung cancer cells.Saudi Pharm J. 2023;31:1139–48. [DOI] [PubMed] [PMC]
Granot-Matok Y, Kon E, Dammes N, Mechtinger G, Peer D. Therapeutic mRNA delivery to leukocytes.J Control Release. 2019;305:165–75. [DOI] [PubMed]
Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer.Nat Rev Immunol. 2018;18:168–82. [DOI] [PubMed] [PMC]
Phua KKL, Leong KW, Nair SK. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format.J Control Release. 2013;166:227–33. [DOI] [PubMed] [PMC]
Lint SV, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy.Cancer Res. 2012;72:1661–71. [DOI] [PubMed]
Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.Nature. 2017;543:248–51. [DOI] [PubMed] [PMC]
Sun X, Zeng L, Huang Y. Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination.J Gene Med. 2019;21:e3089. [DOI] [PubMed]
Callis J, Fromm M, Walbot V. Expression of mRNA electroporated into plant and animal cells.Nucleic Acids Res. 1987;15:5823–31.Erratum in: Nucleic Acids Res. 2021;49:8406. [DOI] [PubMed] [PMC]
Sahin U, Derhovanessian E, Miller M, Kloke B, Simon P, Löwer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.Nature. 2017;547:222–6. [DOI] [PubMed]
Qiu P, Ziegelhoffer P, Sun J, Yang NS. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization.Gene Ther. 1996;3:262–8. [PubMed]
Peking P, Koller U, Hainzl S, Kitzmueller S, Kocher T, Mayr E, et al. A Gene Gun-mediated Nonviral RNA trans-splicing Strategy for Col7a1 Repair.Mol Ther Nucleic Acids. 2016;5:e287. [DOI] [PubMed]
Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, et al. Trial watch: Dendritic cell-based interventions for cancer therapy.Oncoimmunology. 2013;2:e25771. [DOI] [PubMed] [PMC]
Wykes M, Pombo A, Jenkins C, MacPherson GG. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response.J Immunol. 1998;161:1313–9. [PubMed]
Wilgenhof S, Corthals J, Heirman C, Baren Nv, Lucas S, Kvistborg P, et al. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.J Clin Oncol. 2016;34:1330–8. [DOI] [PubMed]
Lesterhuis WJ, de Vries IJM, Schuurhuis DH, Boullart ACI, Jacobs JFM, de Boer AJ, et al. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests.Ann Oncol. 2006;17:974–80. [DOI] [PubMed]
Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer.Nat Rev Immunol. 2005;5:296–306. [DOI] [PubMed]
Khoury HJ, Collins RH Jr, Blum W, Stiff PS, Elias L, Lebkowski JS, et al. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.Cancer. 2017;123:3061–72. [DOI] [PubMed]
Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, et al. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.Clin Cancer Res. 2017;23:1898–909. [DOI] [PubMed] [PMC]
Benteyn D, Heirman C, Bonehill A, Thielemans K, Breckpot K. mRNA-based dendritic cell vaccines.Expert Rev Vaccines. 2015;14:161–76. [DOI] [PubMed]
Gay CL, DeBenedette MA, Tcherepanova IY, Gamble A, Lewis WE, Cope AB, et al. Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.AIDS Res Hum Retroviruses. 2018;34:111–22. [DOI] [PubMed] [PMC]
Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development.Nanotoday. 2019;28:100766. [DOI]
Kauffman KJ, Webber MJ, Anderson DG. Materials for non-viral intracellular delivery of messenger RNA therapeutics.J Control Release. 2016;240:227–34. [DOI] [PubMed]
Zhao M, Li M, Zhang Z, Gong T, Sun X. Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA.Drug Deliv. 2016;23:2596–607. [DOI] [PubMed]
Lungwitz U, Breunig M, Blunk T, Göpferich A. Polyethylenimine-based non-viral gene delivery systems.Eur J Pharm Biopharm. 2005;60:247–66. [DOI] [PubMed]
Rejman J, Tavernier G, Bavarsad N, Demeester J, Smedt SCD. mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers.J Control Release. 2010;147:385–91. [DOI] [PubMed]
Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery.J Control Release. 2006;114:100–9. [DOI] [PubMed]
Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.Mol Ther. 2019;27:710–28. [DOI] [PubMed] [PMC]
Wilson DR, Mosenia A, Suprenant MP, Upadhya R, Routkevitch D, Meyer RA, et al. Continuous microfluidic assembly of biodegradable poly(beta-amino ester)/DNA nanoparticles for enhanced gene delivery.J Biomed Mater Res A. 2017;105:1813–25. [DOI] [PubMed]
Kaczmarek JC, Patel AK, Kauffman KJ, Fenton OS, Webber MJ, Heartlein MW, et al. Polymer-Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs.Angew Chem Int Ed Engl. 2016;55:13808–12. [DOI] [PubMed] [PMC]
Zugates GT, Peng W, Zumbuehl A, Jhunjhunwala S, Huang Y, Langer R, et al. Rapid Optimization of Gene Delivery by Parallel End-modification of Poly(β-amino ester)s.Mol Ther. 2007;15:1306–12. [DOI] [PubMed]
Kaczmarek JC, Kauffman KJ, Fenton OS, Sadtler K, Patel AK, Heartlein MW, et al. Optimization of a Degradable Polymer-Lipid Nanoparticle for Potent Systemic Delivery of mRNA to the Lung Endothelium and Immune Cells.Nano Lett. 2018;18:6449–54. [DOI] [PubMed] [PMC]
Palmiero UC, Kaczmarek JC, Fenton OS, Anderson DG. Poly(β-amino ester)-co-poly(caprolactone) Terpolymers as Nonviral Vectors for mRNA Delivery In Vitro and In Vivo.Adv Healthc Mater. 2018;7:e1800249. [DOI] [PubMed]
Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery.Nat Rev Mater. 2017;2:17056. [DOI]
Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.Proc Natl Acad Sci U S A. 2008;105:11915–20. [DOI] [PubMed] [PMC]
Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, et al. Nonviral delivery of self-amplifying RNA vaccines.Proc Natl Acad Sci U S A. 2012;109:14604–9. [DOI] [PubMed] [PMC]
Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.J Control Release. 2015;217:345–51. [DOI] [PubMed] [PMC]
Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, et al. Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey.Vet Pathol. 2018;55:341–54. [DOI] [PubMed]
Xu S, Yang K, Li R, Zhang L. mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection.Int J Mol Sci. 2020;21:6582. [DOI] [PubMed] [PMC]
Kallen K, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A, et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive® vaccines.Hum Vaccin Immunother. 2013;9:2263–76. [DOI] [PubMed] [PMC]
Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.J Immunother. 2009;32:498–507. [DOI] [PubMed]
Scheel B, Teufel R, Probst J, Carralot J, Geginat J, Radsak M, et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA.Eur J Immunol. 2005;35:1557–66. [DOI] [PubMed]
Kowalczyk A, Doener F, Zanzinger K, Noth J, Baumhof P, Fotin-Mleczek M, et al. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity.Vaccine. 2016;34:3882–93. [DOI] [PubMed]
Amos H. Protamine enhancement of RNA uptake by cultured chick cells.Biochem Biophys Res Commun. 1961;5:1–4. [DOI]
Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.J Immunother. 2011;34:1–15. [DOI] [PubMed]
Schlake T, Thess A, Fotin-Mleczek M, Kallen K. Developing mRNA-vaccine technologies.RNA Biol. 2012;9:1319–30. [DOI] [PubMed] [PMC]
Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.Mol Ther. 2019;27:757–72. [DOI] [PubMed] [PMC]
Sullenger BA, Nair S. From the RNA world to the clinic.Science. 2016;352:1417–20. [DOI] [PubMed] [PMC]
Ulmer JB, Geall AJ. Recent innovations in mRNA vaccines.Curr Opin Immunol. 2016;41:18–22. [DOI] [PubMed]
Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.Nature. 2020;586:567–71. [DOI] [PubMed] [PMC]
Barberis I, Myles P, Ault SK, Bragazzi NL, Martini M. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines.J Prev Med Hyg. 2016;57:E115–20. [PubMed] [PMC]
Kotomina T, Korenkov D, Matyushenko V, Prokopenko P, Rudenko L, Isakova-Sivak I. Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site.Hum Vaccin Immunother. 2018;14:2964–70. [DOI] [PubMed] [PMC]
Del Giudice G, Rappuoli R. Inactivated and adjuvanted influenza vaccines. In: Oldstone M, Compans R, editors. Influenza Pathogenesis and Control - Volume II. Cham: Springer; 2014. pp. 151–80. [DOI] [PubMed]
Javanian M, Barary M, Ghebrehewet S, Koppolu V, Vasigala V, Ebrahimpour S. A brief review of influenza virus infection.J Med Virol. 2021;93:4638–46. [DOI] [PubMed]
Paget J, Spreeuwenberg P, Charu V, Taylor RJ, Iuliano AD, Bresee J, et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project.J Glob Health. 2019;9:020421. [DOI] [PubMed] [PMC]
Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study.Lancet. 2018;391:1285–300.Erratum in: Lancet. 2018;391:1262. [DOI] [PubMed] [PMC]
Feldman RA, Fuhr R, Smolenov I, Ribeiro AM, Panther L, Watson M, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.Vaccine. 2019;37:3326–34. [DOI] [PubMed]
Ebinger JE, Lan R, Sun N, Wu M, Joung S, Botwin GJ, et al. Symptomology following mRNA vaccination against SARS-CoV-2.Prev Med. 2021;153:106860. [DOI] [PubMed] [PMC]
Taaffe J, Ostrowsky JT, Mott J, Goldin S, Friede M, Gsell P, et al. Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact.Vaccine. 2024;42:126408. [DOI] [PubMed] [PMC]
Cugola FR, Fernandes IR, Russo FB, Freitas BC, Dias JLM, Guimarães KP, et al. The Brazilian Zika virus strain causes birth defects in experimental models.Nature. 2016;534:267–71. [DOI] [PubMed] [PMC]
Li X, Dong H, Wang H, Huang X, Qiu Y, Ji X, et al. Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone.Nat Commun. 2018;9:673. [DOI] [PubMed] [PMC]
Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. Modified mRNA Vaccines Protect against Zika Virus Infection.Cell. 2017;168:1114–25.e10.Erratum in: Cell. 2017;169:176. [DOI] [PubMed] [PMC]
Medina-Magües LG, Gergen J, Jasny E, Petsch B, Lopera-Madrid J, Medina-Magües ES, et al. mRNA Vaccine Protects against Zika Virus.Vaccines (Basel). 2021;9:1464. [DOI] [PubMed] [PMC]
Gulick RM, Flexner C. Long-Acting HIV Drugs for Treatment and Prevention.Annu Rev Med. 2019;70:137–50. [DOI] [PubMed]
Haynes BF, Burton DR. Developing an HIV vaccine.Science. 2017;355:1129–30. [DOI] [PubMed] [PMC]
Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection.Proc Natl Acad Sci U S A. 1989;86:6077–81. [DOI] [PubMed] [PMC]
Cu Y, Broderick KE, Banerjee K, Hickman J, Otten G, Barnett S, et al. Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ.Vaccines (Basel). 2013;1:367–83. [DOI] [PubMed] [PMC]
D’haese S, Lacroix C, Garcia F, Plana M, Ruta S, Vanham G, et al. Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV.J Control Release. 2021;330:1016–33. [DOI] [PubMed]
Mu Z, Haynes BF, Cain DW. HIV mRNA Vaccines—Progress and Future Paths.Vaccines (Basel). 2021;9:134. [DOI] [PubMed] [PMC]
Hicks DJ, Fooks AR, Johnson N. Developments in rabies vaccines.Clin Exp Immunol. 2012;169:199–204. [DOI] [PubMed] [PMC]
Velasco-Villa A, Mauldin MR, Shi M, Escobar LE, Gallardo-Romero NF, Damon I, et al. The history of rabies in the Western Hemisphere.Antiviral Res. 2017;146:221–32. [DOI] [PubMed] [PMC]
Wiktor TJ, György E, Schlumberger DH, Sokol F, Koprowski H. Antigenic properties of rabies virus components.J Immunol. 1973;110:269–76. [DOI] [PubMed]
Barth R, Gruschkau H, Bijok U, Hilfenhaus J, Hinz J, Milcke L, et al. A new inactivated tissue culture rabies vaccine for use in man. Evaluation of PCEC-vaccine by laboratory tests.J Biol Stand. 1984;12:29–46. [DOI] [PubMed]
Armbruster N, Jasny E, Petsch B. Advances in RNA Vaccines for Preventive Indications: A Case Study of A Vaccine Against Rabies.Vaccines (Basel). 2019;7:132. [DOI] [PubMed] [PMC]
Zhu G, Zhu C, Zhu Y, Sun F. Minireview of progress in the structural study of SARS-CoV-2 proteins.Curr Res Microb Sci. 2020;1:53–61. [DOI] [PubMed] [PMC]
Hu B, Guo H, Zhou P, Shi Z. Characteristics of SARS-CoV-2 and COVID-19.Nat Rev Microbiol. 2021;19:141–54.Erratum in: Nat Rev Microbiol. 2022;20:315. [DOI] [PubMed] [PMC]
Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.Lancet. 2021;398:2093–100. [DOI] [PubMed] [PMC]
Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Khatib HAA, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.Nat Med. 2021;27:2136–43. [DOI] [PubMed]
Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al.; C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.N Engl J Med. 2022;386:35–46. [DOI] [PubMed] [PMC]
Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation.Nat Rev Drug Discov. 2021;20:817–38.Erratum in: Nat Rev Drug Discov. 2021;20:880. [DOI] [PubMed] [PMC]
Kitano T, Salmon DA, Dudley MZ, Thompson DA, Engineer L. Benefit-Risk Assessment of mRNA COVID-19 Vaccines in Children Aged 6 Months to 4 Years in the Omicron Era.J Pediatric Infect Dis Soc. 2024;13:129–35. [DOI] [PubMed]
Rasool G, Tariq K, Malik IR, Khan AM, Khan WA, Attique B, et al. COVID-19 mRNA Vaccines frontrunners: Evaluation of bio-pharmacological features and antagonistic effects of Pfizer-Biontech and Moderna vaccines.Oxid Commun. 2024;47:486.
Domado AM, Adaza HJF, Beltran APNC, Buenviaje LM, Co CD, Combalicer LR, et al. Antibody titers of individuals vaccinated for COVID-19: A systematic review.J Biosci. 2023;48:32. [DOI] [PubMed]
Lau CS, Oh HML, Aw TC. Reflections on COVID-19: A Literature Review of SARS-CoV-2 Testing.Vaccines (Basel). 2024;13:9. [DOI] [PubMed] [PMC]
Coccia M. Sources, diffusion and prediction in COVID-19 pandemic: lessons learned to face next health emergency.AIMS Public Health. 2023;10:145–68. [DOI] [PubMed] [PMC]
Coccia M. Optimal levels of vaccination to reduce COVID-19 infected individuals and deaths: A global analysis.Environ Res. 2022;204:112314. [DOI] [PubMed] [PMC]
Coccia M. COVID-19 Vaccination is not a Sufficient Public Policy to face Crisis Management of next Pandemic Threats.Public Organ Rev. 2023;23:1353–67. [DOI] [PMC]
Coccia M, Benati I. Negative effects of high public debt on health systems facing pandemic crisis: Lessons from COVID-19 in Europe to prepare for future emergencies.AIMS Public Health. 2024;11:477–98. [DOI] [PubMed] [PMC]
Jeon J, Kim E. Exploring Future Pandemic Preparedness Through the Development of Preventive Vaccine Platforms and the Key Roles of International Organizations in a Global Health Crisis.Vaccines (Basel). 2025;13:56. [DOI] [PubMed] [PMC]
Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, et al. Advances in COVID-19 mRNA vaccine development.Signal Transduct Target Ther. 2022;7:94. [DOI] [PubMed] [PMC]
Magazzino C, Mele M, Coccia M. A machine learning algorithm to analyse the effects of vaccination on COVID-19 mortality.Epidemiol Infect. 2022;150:e168. [DOI] [PubMed] [PMC]
Coccia M. Problem-driven innovations in drug discovery: Co-evolution of the patterns of radical innovation with the evolution of problems.Health Policy Technol. 2016;5:143–55. [DOI]
Coccia M. Sources of technological innovation: Radical and incremental innovation problem-driven to support competitive advantage of firms.Technol Anal Strateg Manag. 2017;29:1048–61. [DOI]
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.N Engl J Med. 2020;383:2603–15. [DOI] [PubMed] [PMC]
Zhang Y, Hu Y, Tian H, Chen X. Opportunities and Challenges for mRNA Delivery Nanoplatforms.J Phys Chem Lett. 2022;13:1314–22. [DOI] [PubMed]
Marra AR, Kobayashi T, Suzuki H, Alsuhaibani M, Tofaneto BM, Bariani LM, et al. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis.J Infect. 2022;84:297–310. [DOI] [PubMed] [PMC]
Prasad S, Kalafat E, Blakeway H, Townsend R, O'Brien P, Morris E, et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy.Nat Commun. 2022;13:2414. [DOI] [PubMed] [PMC]
Petersen MR, Budweg JB, Matar RM. One year follow up for case series of myocarditis following mRNA vaccination against SARS-CoV-2.Am Heart J Plus. 2023;28:100294. [DOI] [PubMed] [PMC]
Wang Y, Kumari M, Chen G, Hong M, Yuan JP, Tsai J, et al. mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications.J Biomed Sci. 2023;30:84. [DOI] [PubMed] [PMC]
Weng Y, Li C, Yang T, Hu B, Zhang M, Guo S, et al. The challenge and prospect of mRNA therapeutics landscape.Biotechnol Adv. 2020;40:107534. [DOI] [PubMed]
Dong Y, Anderson DG. Opportunities and Challenges in mRNA Therapeutics.Acc Chem Res. 2022;55:1. [DOI] [PubMed]
Hu Z, Lu S, Lowrie DB, Fan X. Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development.Front Immunol. 2022;13:895020. [DOI] [PubMed] [PMC]
Reyes-Leiva D, López-Contreras J, Moga E, Pla-Juncà F, Lynton-Pons E, Rojas-Garcia R, et al. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.Neurol Neuroimmunol Neuroinflamm. 2022;9:e200002. [DOI] [PubMed] [PMC]
Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.MMWR Morb Mortal Wkly Rep. 2021;70:977–82. [DOI] [PubMed] [PMC]
Coccia M. Improving preparedness for next pandemics: Max level of COVID-19 vaccinations without social impositions to design effective health policy and avoid flawed democracies.Environ Res. 2022;213:113566. [DOI] [PubMed] [PMC]
Coccia M. Pandemic Prevention: Lessons from COVID-19.Encyclopedia. 2021;1:433–44. [DOI]
